Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 3 3Phase 1 3Phase 4 2Phase 1/2 1

Status

Recruiting 2Terminated 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3

Conditions

Carcinoma, Renal Cell 11Prostatic Neoplasms 3Neoplasms 3Kidney Neoplasms 3Carcinoma 3Pain 2Clear-cell metastatic renal cell carcinoma 2Carcinoma, Medullary 2Carcinoma, Hepatocellular 2von Hippel-Lindau Disease 1Urinary Bladder Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Thyroid cancer, follicular 1Thyroid Neoplasms 1Thyroid Cancer, Papillary 1Refractory Differentiated Thyroid Gland Carcinoma 1Non functioning pancreatic endocrine tumor 1Neuroendocrine Tumors 1Lymphatic Metastasis 1Liver Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Adenoma, Islet Cell 1Adenocarcinoma, Follicular 1

Interventions

Interferon-alpha 7aldesleukin 6Sunitinib 6Radiotherapy 5Nivolumab 5Doxorubicin 5Vincristine 4Ipilimumab 4Filgrastim 4Dactinomycin 4Chemotherapy, Adjuvant 4Axitinib 4cabozantinib 3Sorafenib 3Everolimus 3Etoposide 3Cyclophosphamide 3temsirolimus 2pembrolizumab 2Ifosfamide 2G250 monoclonal antibody 2Fluorouracil 2Carboplatin 2Bevacizumab 2vitespin 1shark cartilage extract 1pazopanib 1lenvatinib 1glutamic acid diethyl ester 1cemiplimab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 3 × Kidney Neoplasms × cabozantinib × Clear all
NCT07011719 2026-05-14

Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

Arcus Biosciences, Inc.

Phase 3 Recruiting
720 enrolled
Genitourinary

Clear-cell metastatic renal cell carcinoma, Kidney Neoplasms

NCT06364631 2025-01-16

CARE1

Gustave Roussy, Cancer Campus, Grand Paris

Phase 3 Recruiting
1,250 enrolled
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

NCT03729245 2023-04-11

A Study of Bempegaldesleukin (NKTR-214: BEMPEG) in Combination With Nivolumab Compared With the Investigator's Choice of a Tyrosine Kinase Inhibitor (TKI) Therapy (Either Sunitinib or Cabozantinib Monotherapy) for Advanced Metastatic Renal Cell Carcinoma (RCC)

Nektar Therapeutics

Phase 3 Terminated
623 enrolled 14 charts
Genitourinary

Carcinoma, Renal Cell, Kidney Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡